Use of a rare disease patient registry in long-term post-authorisation drug studies: a model for collaboration with industry

Lancet Respir Med. 2018 Jul;6(7):495-496. doi: 10.1016/S2213-2600(18)30192-9. Epub 2018 May 4.
No abstract available

Publication types

  • Review

MeSH terms

  • Cooperative Behavior*
  • Drug Industry*
  • Humans
  • Product Surveillance, Postmarketing / methods*
  • Rare Diseases*
  • Registries*
  • United Kingdom